Previous 10 | Next 10 |
2023-04-05 11:05:28 ET Arcutis Biotherapeutics ( NASDAQ: ARQT ) said its plaque psoriasis cream Zoryve is being covered without prior authorizations by an additional eight national and regional health plans, effective April 1. The company noted that, combined with the pre...
Eight additional national and regional health plans are now covering ZORYVE for plaque psoriasis ZORYVE is a once-daily, steroid-free cream approved for use in both adults and adolescents with plaque psoriasis, including all affected areas of the body WESTLAKE VILLAGE, Calif., April...
New INTEGUMENT-1 and INTEGUMENT-2 data show a rapid and significant reduction in itch as early as 24 hours after the first application of roflumilast cream 0.15% Rapid and significant improvements were achieved including individuals reaching a 75% reduction of Eczema Area and Severity Index (...
2023-03-11 10:00:00 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports a...
2023-03-10 15:00:56 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calenda...
Late breaking session to highlight new data from the INTEGUMENT Phase 3 trials evaluating roflumilast cream in atopic dermatitis New national survey insights depicting disease burden, path to diagnosis and treatment patterns for seborrheic dermatitis New clinical safety and efficacy data ...
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2022 Earnings Conference Call February 28, 2023 04:30 PM ET Company Participants Eric McIntyre - Head of Investor Relations Frank Watanabe - President & Chief Executive Officer Patrick Burnett - Chief Medical Officer Ken ...
Arcutis Biotherapeutics press release ( NASDAQ: ARQT ): Q4 GAAP EPS of -$1.18 beats by $0.27 . Revenue of $2.96M beats by $0.91M . For further details see: Arcutis Biotherapeutics Q4 results beat estimates
The following slide deck was published by Arcutis Biotherapeutics, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Arcutis Biotherapeutics, Inc. 2022 Q4 - Results - Earnings Call Presentation
Achieved net revenues of $3.0 million for ZORYVE® (roflumilast) cream 0.3% in the first full quarter since the August 2022 launch, driven by continued unit demand growth Secured expanded commercial payer coverage for ZORYVE in plaque psoriasis with the second of the top three pharmacy be...
News, Short Squeeze, Breakout and More Instantly...
Arcutis Biotherapeutics Inc. Company Name:
ARQT Stock Symbol:
NASDAQ Market:
Arcutis Biotherapeutics Inc. Website:
ZORYVE cream provides rapid relief, with efficacy, safety, and tolerability demonstrated up to 56 weeks of treatment ZORYVE cream rapidly and significantly reduces itch, the most bothersome symptom of atopic dermatitis (AD) Once-daily cream is for use anywhere on the body for any duration...
WESTLAKE VILLAGE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the Company has been in communication with the U....
2024-06-16 18:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...